DySMA – an Instrument to Monitor Swallowing Function in Children with Spinal Muscular Atrophy ages 0 to 24 Months: Development, Consensus, and Pilot Testing
Journal of Neuromuscular Diseases · 2024
DOI: 10.3233/jnd-230177 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Neuromuscular Diseases, 2024. Verfasst von Jana Zang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Voice, Speech and Hearing Disorders, University Dysphagia Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Deglutition Disorders, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The manifestation of bulbar symptoms, especially swallowing, is important for evaluating disease-modifying therapies for spinal muscular atrophy (SMA). Due to the lack of instruments, the topic is still underrepresented in research.
Objective
This study aimed to develop a tool to monitor swallowing development in children aged 0 to 24 months with SMA.
Methods
The method was guided by the COSMIN guidelines and followed a multi-stage Delphi process. The first step was a rapid review of swallowing outcomes in children with SMA younger than 24 months. In the second step, online group interviews with experts ( n = 7) on dysphagia in infants were conducted, followed by an anonymous online survey among experts in infants with SMA ( n = 19). A predefined consensus threshold for nominal scaled voting was set at≥75 % and for 5-point Likert scale voting at 1.25 of the interquartile range. The third step was the pilot test of the instrument, performed with three groups (healthy controls n = 8; pre-symptomatic n = 6, symptomatic n = 6).
Results
Based on the multi-level interprofessional consensus, the DySMA comprises two parts (history and examination), ten categories, with 36 items. Implementation and scoring are clearly articulated and easy to implement. The pilot test showed that swallowing development could be recorded in all groups.
Conclusion
The DySMA is well suited for monitoring swallowing development in pre-symptomatic and symptomatic treated infants with SMA. It can be performed in a time-efficient and interprofessional manner. The resulting score is comparable to results from other instruments measuring other domains, e.g., motor function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Voice, Speech and Hearing Disorders, University Dysphagia Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Medical Psychology, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Zitieren
APA
Zang, J., Witt, S., Johannsen, J., Weiss, D., Denecke, J., Dumitrascu, C., Nießen, A., Quitmann, J. H., Pflug, C., & Flügel, T. (2024). DySMA – an Instrument to Monitor Swallowing Function in Children with Spinal Muscular Atrophy ages 0 to 24 Months: Development, Consensus, and Pilot Testing. Journal of Neuromuscular Diseases. https://doi.org/10.3233/jnd-230177
Vancouver
Zang J, Witt S, Johannsen J, Weiss D, Denecke J, Dumitrascu C, et al. DySMA – an Instrument to Monitor Swallowing Function in Children with Spinal Muscular Atrophy ages 0 to 24 Months: Development, Consensus, and Pilot Testing. Journal of Neuromuscular Diseases. 2024. doi:10.3233/jnd-230177
BibTeX
@article{Zang2024,
author = {Zang, Jana and Witt, Stefanie and Johannsen, Jessika and Weiss, Deike and Denecke, Jonas and Dumitrascu, Charlotte and Nießen, Almut and Quitmann, Julia Hannah and Pflug, Christina and Flügel, Till},
title = {DySMA – an Instrument to Monitor Swallowing Function in Children with Spinal Muscular Atrophy ages 0 to 24 Months: Development, Consensus, and Pilot Testing},
journal = {Journal of Neuromuscular Diseases},
year = {2024},
doi = {10.3233/jnd-230177}
}
EUVIMED